Day: February 27, 2025

PALO ALTO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) — HP (NYSE: HPQ)First quarter GAAP diluted net earnings per share (“EPS”) of $0.59, within the previously provided outlook of $0.57 to $0.63 per share First quarter non-GAAP diluted net EPS of $0.74, within the previously provided outlook of $0.70 to $0.76 per share First quarter net revenue of $13.5 billion, up 2.4% from the prior-year period First quarter net cash provided by operating activities of $0.4 billion, free cash flow of $0.1 billion First quarter returned $0.4 billion to shareholders in the form of share repurchases and dividends Estimated $300 million increase in Future Ready plan annualized gross run rate structural cost savings, to $1.9 billion by end of fiscal year 2025 and estimated $150 million increase in restructuring and other charges to approximately...

–  Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling; expected to be substantially enrolled by YE25 –  Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update planned for 1H25 –  Petosemtamab evaluation in mCRC ongoing in combination with standard chemotherapy in 1L and 2L and monotherapy in 3L+; mCRC initial clinical data planned for 2H25 –  Based on the Company’s current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus’ operations into 2028 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our),...

Conference call begins at 4:30 p.m. Eastern time today MIAMI, Feb. 27, 2025 (GLOBE NEWSWIRE) — OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2024. Highlights from the fourth quarter of 2024 and recent weeks include the following:Enrollment and dosing underway by Merck in the Phase 1 Epstein-Barr virus (EBV) vaccine trial. Dosing of patients has commenced for the Phase I study (NCT06655324) of an EBV vaccine candidate being developed in collaboration with Merck. The investigational vaccine, based on ModeX’s ferritin nanoparticle vaccine platform, is being evaluated for safety and tolerability in up to 200 healthy adults. Commencement of this study triggered a milestone payment to ModeX. Awarded $51 million of additional funding under an existing...

— Record Fourth Quarter Net Sales Rise 4.7 Percent to $1.81 Billion —— Net Sales, Adjusted for Changes in Foreign Currency Rise 7.8 Percent in the 2024 Fourth Quarter —— Gross Profit as a Percentage of Net Sales Improves to 55.5 Percent on a Non-GAAP Adjusted Basis (55.3 Percent on a Reported Basis) in the 2024 Fourth Quarter –— Operating Income Rose 7.9 Percent to $517.9 Million on a Non-GAAP Adjusted Basis —— Net Income Per Diluted Share was $0.38 on a Non-GAAP Adjusted Basis ($0.28 on a Reported Basis) in the 2024 Fourth Quarter — CORONA, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) — Monster Beverage Corporation (NASDAQ: MNST) today reported financial results for the three- and twelve-months ended December 31, 2024. Items Impacting Profitability The tables at the end of this press...

Conference Call and Webcast scheduled for tomorrow, February 28, 2025 at 10:00 am MT EAGLE, Idaho, Feb. 27, 2025 (GLOBE NEWSWIRE) — The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, today announced its operating results for the fiscal year and fourth quarter of 2024, reporting GAAP diluted earnings per share of $0.70 and $0.16 for the year ended December 31, 2024 and the fourth quarter, respectively. Pennant also reported adjusted diluted earnings per share of $0.94 for the year and $0.24 for the quarter (1). Fourth Quarter HighlightsTotal revenue for the full year was $695.2 million, an increase of $150.3 million or 27.6% over the prior year, and for the fourth quarter was $188.9 million, an increase of $42.9 million or 29.4% over the...

MINNEAPOLIS, Feb. 27, 2025 (GLOBE NEWSWIRE) — Jamf (NASDAQ: JAMF), the standard in managing and securing Apple at work, today announced financial results for its fourth quarter and full year ended December 31, 2024, through an earnings release available on the company’s Investor Relations website at https://ir.jamf.com. The earnings release will be furnished to the SEC on Form 8-K. Jamf will host a conference call and live webcast for analysts and investors at 3:30 p.m. Central Time (4:30 p.m. Eastern Time) on February 27, 2025. The conference call will be webcast live on Jamf’s Investor Relations website at https://ir.jamf.com. Those parties interested in participating via telephone may register on Jamf’s Investor Relations website. The financial tables, earnings presentation, and investor presentation provided in connection with...

Fourth quarter and full year 2024 revenue exceeded guidance FRAMINGHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) — Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter and full year ended December 31, 2024.  Fourth Quarter 2024 Financial Highlights:Revenue was $62.3 million, a decrease of 6% from $65.9 million in Q4 2023.  Net Loss, inclusive of goodwill impairment charges of $97.1 million, was $(84.7) million, or (136)% of revenue, compared to $(13.4) million or (20)% of revenue in Q4 2023.   Adjusted Net Income was $12.6 million, compared to $10.6 million in Q4 2023.    Adjusted EBITDA was $17.5 million, or 28% of revenue, compared to $19.8 million, or 30% of revenue in Q4 2023.   Cash Flow...

BURLINGTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) — LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants, and services, reported Q4 2024 results, announced an increased quarterly dividend of $0.20/share (+25%), and provided guidance. Q4 2024 Financial ResultsSales $55.7mm, +14% (+14% organic) vs. Q4 2023 Gross margin 69.3%, +121 bps Op. income $12.9mm, +26% Op. margin 23% Earnings per diluted share $0.49, +30% Cash up $175.8mm sequentially to $299.7mmGrafts (+23%), carotid shunts (+14%) and catheters (+12%) drove Q4 sales growth. APAC sales increased 21%, EMEA 18% and the Americas 12%. XenoSure patches received Chinese cardiac approval in December. The gross margin improved to 69.3% (vs. 68.1% in Q4 2023), due to higher ASPs and manufacturing efficiencies. Operating income of $12.9mm was up 26% in Q4. Operating...